PALO ALTO, Calif. – BridgeBio Pharma, Inc. (NASDAQ:BBIO), a biopharmaceutical company specializing in genetic diseases and cancers, today announced the commencement of a $250 million underwritten public offering of its common stock. In addition, the company plans to offer underwriters a 30-day option to purchase up to an extra $37.5 million in common stock.
The offering, which is contingent on market conditions and other factors, will see all shares sold by BridgeBio. The financial institutions J.P. Morgan, Cantor Fitzgerald & Co., and Mizuho are serving as joint book-running managers, with Raymond James as the lead manager.
BridgeBio's offering comes from an effective shelf registration statement on Form S-3ASR filed with the U.S. Securities and Exchange Commission (SEC) on May 4, 2023, which was automatically effective upon filing. The terms of the offering will be outlined in a prospectus supplement and the accompanying prospectus, part of the registration statement.
Details regarding the final terms of the offering will be available in a final prospectus supplement to be filed with the SEC. It is important to note that this press release does not constitute an offer to sell or a solicitation of an offer to buy the securities, and there will be no sale of these securities in any state or jurisdiction where such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Founded in 2015, BridgeBio aims to deliver transformative medicines for genetic diseases and cancers with clear genetic drivers. The company's development programs span from early science to advanced clinical trials.
The information in this article is based on a press release statement from BridgeBio Pharma, Inc. and does not include any assumptions or commentary on the reported facts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.